In the latest vaccine news, a new study has found that booster jabs produce long-lasting T-cells that are likely to work against all current and future coronavirus variants, including omicron.
Data from the government-funded Covboost trial has been published in The Lancet and reveals how effective different vaccines are as boosters when it comes to enhancing levels of T-cells and antibodies.
It found that six vaccines — Pfizer/BioNTech, Oxford/AstraZeneca, Janssen, Moderna, CureVac and Novavax — gave a significant immune boost, irrespective of what vaccine a person received for the first two doses.
Pfizer and Moderna were found to be the most effective and people who received two doses of AstraZeneca saw their antibody levels soar 32-fold after Moderna, the most effective jab, and 24.5-fold for Pfizer.
These two jabs also gave the most dramatic increase for those who originally got two doses of Pfizer, increasing antibody levels 12 and nine-fold for Moderna and Pfizer, respectively.
Joe Pinkstone explains the science in more detail here.